ClinicalTrials.gg
CompletedNCT05945706Updated Mar 14, 2025

Evaluation of Renal Resistive Index in Patients with Controlled Hypotension

An observational study in Acute Kidney Injury, Hypotension, Controlled and Renal Failure, sponsored by Ankara Diskapi Training and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by Ankara Diskapi Training and Research Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
65
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Acute Kidney Injury with a site in Turkey — 21 open to participants now, 22 under way, none of them phase 3. Acute Kidney Injury · Turkey.

Enrollment
56th of 73
65 · median 130
Started
2023
with 10 others
Observational
73 of 90
15 open now
Registered
32nd of 90
by date
Lead sponsor
2 of 90
Ankara Diskapi Training and Research Hospital

Among the 90 studies in Acute Kidney Injury with a site in Turkey, this one is the 56th largest by enrollment of the 73 observational ones that give a count, is one of 11 that started in 2023, is one of 73 observational ones, and was the 32nd registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

21 of the 90 studies in Acute Kidney Injury with a site in Turkey are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Acute Kidney Injury with a site in Turkey, or all of them as a file.
02

Study summary

In recent studies, it has been reported that the renal resistive index is effective in detecting postoperative acute kidney injury in the early period. This study aims to evaluate the preoperative and postoperative renal resistive index variation with intraoperative controlled hypotension and research the renal resistive index's utility in the early detection of renal dysfunction that may develop after surgery.

Read the detailed description

Controlled hypotension could be defined as a reduction of the systolic blood pressure to 80-90 mmHg, a reduction of mean arterial pressure (MAP) to 50-65 mmHg, or a 30% reduction of baseline MAP (1). It is frequently applied in orthopedics, neurosurgery, and ear-nose-throat surgeries to reduce blood loss and provide a good field of view to the surgeon. However, the combination of hypotension with hypovolemia may result in postoperative acute kidney injury (AKI), especially in the elderly and in patients with hypoperfusion-sensitive disease. The situation may worsen with nephrotoxic drugs.

In patients with AKI, the length of hospital stay is prolonged, and the risk of morbidity and mortality increases, so early detection of AKI is significant. Perioperative AKI diagnosis is difficult and often delayed. Although there are various tests (cystatin-c, urea, serum creatinine, creatinine clearance, etc.), there is still no early, accurate, easy-to-use AKI marker in clinical practice.

The most commonly used guidelines for AKI classification are 2004-RIFLE (Risk, Injury, Failure, Loss of kidney function, End stage renal disease), 2007-AKIN (Acute Kidney Injury Network), and 2012-KDIGO (Kidney Disease Improving Global Outcomes). Based on the validity of the RIFLE and AKIN criteria, the KDIGO guideline was developed to diagnose AKI with a straightforward definition for clinical practice.

Doppler ultrasonography is widely used in the evaluation of chronic kidney diseases. Renal resistive index (RRI), one of the Doopler-derived indices, is calculated by imaging the intrarenal (arcuate or interlobar) artery and measuring the highest systolic and lowest end-diastolic blood flow velocity using a colored Doppler. It is generally accepted that the normal value of the RRI is 0.60 ± 0.01 (mean±SD), and there is a general opinion that the upper limit of the RRI is 0.7 (2). The renal resistive index has been used for years to diagnose and follow up on various kidney diseases (evaluation of chronic renal allograft rejection, detection and management of renal artery stenosis, and chronic differential diagnosis) (3). Recent studies have reported that RRI effectively detects postoperative AKI in the early period before the criteria for AKIN are formed (4-5).

This study aims to evaluate the preoperative and postoperative renal resistive index variation with intraoperative controlled hypotension and research the renal resistive index's utility in the early detection of renal dysfunction that may develop after surgery.

03

Conditions studied

  • Acute Kidney Injury
  • Hypotension, Controlled
  • Renal Failure
  • Ultrasonography, Doppler

Keywords

  • acute kidney injury
  • blood flow velocity
  • Renal Doppler ultrasound
  • Renal Resistive Index
  • Controlled hypotension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All ASA I-II-III patients who are scheduled to undergo elective arthroscopic shoulder surgery older than 18 years old

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18 years old
  • will undergo elective arthroscopic shoulder surgery
  • ASA ( Classification) I-II or III

Exclusion criteria

Exclusion Criteria:

  • Cardiac arrhythmia
  • Asymmetric kidney disease
  • Poor echogenicity (for imaging)
  • Chronic renal dysfunction (\<30)
  • Renal artery stenosis
  • Endocarditis
  • Postoperative agitation or confusion
  • Postoperative polypnea >35/min or respiratory failure
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
65 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Renal resistive index

    Renal resistive index measurement by Doppler ultrasonography before anesthesia induction

    Time frame: baseline, pre-surgery

  2. Renal resistive index

    Renal resistive index measurement by Doppler ultrasonography at the end of surgery under anesthesia

    Time frame: immediately after the surgery under anesthesia

  3. Renal resistive index

    Renal resistive index measurement by Doppler ultrasonography in the postanesthetic care unit

    Time frame: within 30 minutes after surgery

Secondary outcomes

  1. serum creatinine

    blood serum creatinine level at admission to the hospital

    Time frame: preoperative (baseline)

  2. serum creatinine

    blood serum creatinine level on postoperative day one

    Time frame: postoperative day 1

  3. serum creatinine

    blood serum creatinine level on postoperative day two

    Time frame: postoperative day 2

  4. postoperative urine output

    postoperative urine output measurement

    Time frame: every 6 hours for 48 hours

07

Study locations

1 site
  • Dıskapı Training and Research Hospital
    Ankara, Altındağ 06110, Turkey
08

References and documents

Publications

  • Xu N, Chen L, Liu L, Rong W. Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis. PLoS One. 2023 Jan 17;18(1):e0278846. doi: 10.1371/journal.pone.0278846. eCollection 2023. PubMed 36649357 ↗
  • Tublin ME, Bude RO, Platt JF. Review. The resistive index in renal Doppler sonography: where do we stand? AJR Am J Roentgenol. 2003 Apr;180(4):885-92. doi: 10.2214/ajr.180.4.1800885. No abstract available. PubMed 12646425 ↗
  • Marty P, Ferre F, Labaste F, Jacques L, Luzi A, Conil JM, Silva S, Minville V. The Doppler renal resistive index for early detection of acute kidney injury after hip fracture. Anaesth Crit Care Pain Med. 2016 Dec;35(6):377-382. doi: 10.1016/j.accpm.2015.12.013. Epub 2016 Apr 28. PubMed 27133237 ↗
  • Bossard G, Bourgoin P, Corbeau JJ, Huntzinger J, Beydon L. Early detection of postoperative acute kidney injury by Doppler renal resistive index in cardiac surgery with cardiopulmonary bypass. Br J Anaesth. 2011 Dec;107(6):891-8. doi: 10.1093/bja/aer289. Epub 2011 Sep 22. PubMed 21940396 ↗
  • Viazzi F, Leoncini G, Derchi LE, Pontremoli R. Ultrasound Doppler renal resistive index: a useful tool for the management of the hypertensive patient. J Hypertens. 2014 Jan;32(1):149-53. doi: 10.1097/HJH.0b013e328365b29c. PubMed 24172238 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Oct 2023, 3 months.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 3 months is below that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2023
First posted
Jul 14, 2023
StartActual
Jul 1, 2023
Primary completionActual
Oct 1, 2023
CompletionActual
Dec 31, 2023
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05945706
Lead sponsor
Ankara Diskapi Training and Research Hospital
Responsible party
Fatma Özkan Sipahioğlu (MD, Specialist, Principal Investigator, Ankara Diskapi Training and Research Hospital) — Principal investigator
First posted
Jul 14, 2023
Start date
Jul 1, 2023
Primary completion
Oct 1, 2023
Completion
Dec 31, 2023
Last update
Mar 14, 2025

Study contacts

Fatma Ozkan Sipahioglu, MD
principal investigator · Ankara Diskapi Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion